Evidence map›Paper›PMID 33050021›Full record

ReviewCells2020

Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility.

Sahar Esfandyari, Rishi Man Chugh, Hang-Soo Park, Elie Hobeika, Mara Ulin, Ayman Al-Hendy

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sahar EsfandyariDepartment of Surgery, University of Illinois at Chicago, 820 South Wood Street, Chicago, IL 60612, USA.
Rishi Man ChughDepartment of Surgery, University of Illinois at Chicago, 820 South Wood Street, Chicago, IL 60612, USA.
Hang-Soo ParkDepartment of Surgery, University of Illinois at Chicago, 820 South Wood Street, Chicago, IL 60612, USA.
Elie HobeikaFertility Centers of Illinois, Glenview, IL 60026, USA.
Mara UlinDepartment of Surgery, University of Illinois at Chicago, 820 South Wood Street, Chicago, IL 60612, USA.ORCID 0000-0002-4636-6396
Ayman Al-HendyDepartment of Surgery, University of Illinois at Chicago, 820 South Wood Street, Chicago, IL 60612, USA.
University of Illinois Chicago · USFertility Centers of Illinois · US

Funding

Investigating the effectiveness of COVID-19 testing choices, community engagement, and culturally-embedded mHealth literacy delivery in a medically-underserved, community-based sampleR01ES028615 · NIEHS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI AL-HENDY, AYMAN, WALKER, CHERYL L. · 2017 to 2022
$5.0M
NIEHS NIH HHS R01 ES028615
6 · The paper itself

Abstract

Female infertility is a global medical condition that can be caused by various disorders of the reproductive system, including premature ovarian failure (POF), polycystic ovary syndrome (PCOS), endometriosis, Asherman syndrome, and preeclampsia. It affects the quality of life of both patients and couples. Mesenchymal stem cells (MSCs) have received increasing attention as a potential cell-based therapy, with several advantages over other cell sources, including greater abundance, fewer ethical considerations, and high capacity for self-renewal and differentiation. Clinical researchers have examined the therapeutic use of MSCs in female infertility. In this review, we discuss recent studies on the use of MSCs in various reproductive disorders that lead to infertility. We also describe the role of microRNAs (miRNAs) and exosomal miRNAs in controlling MSC gene expression and driving MSC therapeutic outcomes. The clinical application of MSCs holds great promise for the treatment of infertility or ovarian insufficiency, and to improve reproductive health for a significant number of women worldwide.

Indexed as

Exosome Multienzyme Ribonuclease ComplexFemaleHumansInfertility, FemaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMicroRNAsOvarian FolliclePrimary Ovarian InsufficiencyExosome Multienzyme Ribonuclease ComplexMicroRNAsinfertilitymesenchymal stem cells (MSCs)reproductive systemstem-cell therapy

Identifiers

PMID33050021
PMCPMC7599919
OpenAlexW3085783016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.